Co-drugs of aminosalicylates and nutraceutical amino sugar for ulcerative colitis

Journal of Drug Delivery Science and Technology

Volumn 21, Issue 6, 2011, Pages 527-533

  Dhaneshwar, S S ^a   Sharma, M ^a   Vadnerkar, G ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

4 aminosalicylic acid; 5 aminosalicylic acid; Co drug; D glucosamine; Ulcerative colitis

Indexed keywords

AMINOSUGAR; GLUCOSAMINE; MESALAZINE; MYELOPEROXIDASE; NUTRACEUTICAL; PRODRUG; SALAZOSULFAPYRIDINE; TRINITROBENZENESULFONIC ACID;

ARTICLE; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; NONHUMAN; PARTITION COEFFICIENT; ULCERATIVE COLITIS;

EID: 84255193439     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(11)50085-1     Document Type: Article

References (33)

1. Crohn's and Colitis Foundation of America Inc. - About ulcerative colitis and proctitis. - Available at: http://www.ccfa.org/info/ about/ucp [Accessed on 26 February 2009].
2. National Digestive Diseases Information Clearing House. - Ulcerative colitis. - Available at: http://www.niddk.nih.gov/health/ digest/pubs/colitis/ colitis.htm [Accessed on 03 May 2010].
3. Head K.A., Jurenka J.S. - Inflammatory bowel disease. Part 1: Ulcerative colitis, Pathophysiology and conventional and alternative treatment options. - Alt. Med. Review., 8 (3), 247-283, 2003. (Pubitemid 37099887)
4. Nagpal D., Singh R., Gairola N., Bodhankar S.L., Dhaneshwar S.S. - Mutual azo prodrug of 5- aminosalicylic acid for colon targeted drug delivery: synthesis, kinetic studies and pharmacological evaluation. - Ind. J. Pharm. Sci., 68 (2), 171-178, 2006. (Pubitemid 43900592)
5. Dhaneshwar S.S., Gairola N., Kandpal M., Vadnerkar G., Bhatt L., Rathi B., Kadam S.S. - Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5- aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. - Eur. J. Med. Chem., 44, 3922-3929, 2009.
6. Vadnerkar G., Dhaneshwar S. - Design and development of latentiated strategy for delivery of mesalazine to colon. - J. Drug Del. Sci. Tech., 19 (5), 321-329, 2009.
7. Dhaneshwar S. S., Kandpal M., Vadnerkar G. - L-Glutamine conjugate of meselamine: a novel approach for targeted delivery to colon. - J. Drug Del. Sci. Tech., 19 (1), 67-72, 2009.
8. Wahl C., Liptay S., Adler G., Schmid R.M. - Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. - J. Clin. Invest., 101, 1163-1174, 1998. (Pubitemid 28125296)
9. Cipolla G., Crema F., Sacco S., Mora E., de Ponti F., Frigo G. -Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. - Pharmacol. Res., 46, 1-6, 2002. (Pubitemid 35300786)
10. Jani N., Regueiro M.D. - Medical therapy for ulcerative colitis. - Gastroenterol. Clin. North Am., 31, 147-166, 2002.
11. Marteau P., Nelet F., Le Lu M., Devaux C. - Adverse events in patients treated with aminosalicylic acid: 1993-1994 pharmacovigilance report for pentasa in France. - Aliment. Pharmacol. Ther., 10, 949-956, 1996. (Pubitemid 26412924)
12. Ransford R.A., Langman M.J.- Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. - Gut, 51, 536-539, 2002.
13. Decocq G., Gras-Champel V., Vrolant-Mille C., Delcenserie R., Sauvé L. - Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature. -Therapie, 54, 41-48, 1999. (Pubitemid 29145970)
14. Daniel F., Seksik P., Cacheux W., Jian R., Marteau P. -Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis. - Inflamm. Bowel Dis., 10, 258-260, 2004.
15. Hanauer S.B., Baert F. - Medical therapy of inflammatory bowel disease. - Med. Clin. North Am., 78, 1413-1426, 1994. (Pubitemid 24359177)
16. Symonds D.A. - The glycosaminoglycans of the human colon in inflammatory and neoplastic conditions. - Arch. Pathol. Lab. Med., 102, 146-149, 1978. (Pubitemid 8300707)
17. Murch S.H., MacDonald T.T., Walker-Smith J.A., Levin M., Lionetti P., Klein N.J. - Disruption of sulphated glycosaminoglycans in intestinal inflammation. - Lancet, 341, 711-714, 1993. (Pubitemid 23085176)
18. Vantrappen G., Geboes K. - Glycosaminoglycans and the gut. - Lancet, 341, 730-731, 1993.
19. Goodman M.J., Skinner J.M., Truelove S.C - Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn's disease. - Gut, 18, 219-228, 1977. (Pubitemid 8080133)
20. Salvatore S., Heuschkel R., Tomlin S., Davies S.E., Edwards S., Walker-Smith J.A. French I., Murch S.H. - A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in pediatric chronic inflammatory bowel disease. - Aliment. Pharmacol. Ther., 14 (12), 1567-1579, 2000.
21. Yomogida S., Hua S.J., Sakamoto K., Nagaoka I. - Glucosamine suppresses the interleukin-8 production and ICAM-1 expression by TNF-α-stimulated human colonic epithelial cell line HT- 29. - Int. J. Mol. Med, 22, 205-211, 2008.
22. Yomogida S., Kojima Y., Tsutsumi-ishii Y., Hua J., Sakamoto K., Nagaoka I. - Glucosamine, a naturally occurring amino monosaccharide, suppresses dextran sulfate sodium-induced colitis in rats. - Int. J. Mol. Med., 22, 317-323, 2008.
23. Wallace J.L., Cirino G., Caliendo G., Sparatore A., Santagada V., Fiorucci S. - US Patent 12/368846, 2009.
24. Nielsen N.M., Bundgaard H. - Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. - J. Med. Chem., 32, 727-734, 1989. (Pubitemid 19075734)
25. Jung Y.J., Lee J.S., Kim Y.M. - Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. - J. Pharm. Sci., 90, 1767-1775, 2001. (Pubitemid 33062597)
26. Yamada T., Marshall S., Specian R.D., Grisham M.B. - A comparative analysis of two models of colitis in rats. - Gastroenterol., 102, 1524-1534, 1992.
27. Hartmann G., Bidlingamaier C., Seigmund B., Albrich S., Schulze J., Tschoep K., Eigler A., Lehr H.A., Endres S. - Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. - J. Pharmacol. Exp. Ther., 292 (1), 22-30, 2000. (Pubitemid 30026352)
28. Krawisz J.E., Sharon P., Stenson W.F. - Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. - Gastroenterol., 87, 1344-1350, 1984. (Pubitemid 15201434)
29. Rainsford K.D., Whitehouse M.W.-Anti-inflammatory/anti-pyretic salicylic acid esters with low gastric ulcerogenic activity. - Inflammation Res., 10 (5), 451-456, 1980. (Pubitemid 11160920)
30. Rainsford K.D. - A synergistic interaction between aspirin, or other non-steroidal anti-inflammatory drugs, and stress which produces severe gastric mucosal damage in rats and pigs. Agents Actions, 5, 553-558, 1975.
31. Cioli V., Putzolu S., Rossi V., Corza B.P., Corradino C. - The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. - Toxicol. Appl. Pharmacol., 50, 283-289, 1979. (Pubitemid 10233388)
32. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuck M.R., Wallace J.L. - Hapten-induced model of chronic inflammation and ulceration in the rat. - Gastroenterol., 96, 795-803, 1989. (Pubitemid 19057602)
33. Zingarelli B., Squadrito F., Graziani F., Camerini R., Caputi A.P. - Effects of zileuton, a new 5- lipoxygenase inhibitor, in experimentally induced colitis in rats. - Agents Actions, 39, 150-156, 1993. (Pubitemid 23349824)